Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus IBUPROFEN AND DIPHENHYDRAMINE CITRATE.
Head-to-head clinical analysis: ALEVE D SINUS COLD versus IBUPROFEN AND DIPHENHYDRAMINE CITRATE.
ALEVE-D SINUS & COLD vs IBUPROFEN AND DIPHENHYDRAMINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing pain, fever, and inflammation. Diphenhydramine citrate is an antihistamine that antagonizes histamine H1 receptors, producing sedative and anticholinergic effects.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Ibuprofen 200 mg + Diphenhydramine citrate 38 mg (equivalent to diphenhydramine HCl 25 mg) orally every 4-6 hours as needed, not to exceed Ibuprofen 1200 mg/day or Diphenhydramine citrate 152 mg/day.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Ibuprofen: terminal elimination half-life approximately 1.8-2.5 hours in adults; prolonged in elderly and patients with hepatic impairment. Diphenhydramine: terminal elimination half-life ranges from 4 to 10 hours (mean 7 hours); may be prolonged in elderly and hepatic impairment.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Ibuprofen: renal elimination of metabolites (approximately 90%) and unchanged drug (approximately 10%); fecal elimination <5%. Diphenhydramine: primarily renal elimination (approximately 60-70% as metabolites, 1-2% unchanged); fecal elimination approximately 10-15%.
Category C
Category D/X
NSAID/Decongestant Combination
NSAID